RFPs

NIAID BAA To Support In Vitro Diagnostic Product Development

Dear All, Excitingly, NIAID has released a new BAA (Broad Agency Announcement) entitled “Diagnostics Pre-Clinical Services Program.” Similar to the prior BAA for support of biopharmaceutical product development, this new BAA for diagnostic devices seeks a group who can manage a “multiple award Indefinite Delivery/Indefinite Quantity (IDIQ) type contract” (read that slowly!) and through it offer a comprehensive

Read More »

FORWARD Act, PREVENT Act, new NIAID RFP!

Dear All, Our US government colleagues have been busy! Three things back-to-back: First, the FORWARD Act (Finding Orphan-disease Remedies With Antifungal Research and Development Act of 2022”) was introduced in the US Senate on 13 Jan 2021 as S.3498 by Sens. Kelly, Sinema, and Feinstein. You’ve got to admire the acronymics! The Senate bill is the

Read More »

CDC BAA: Surveillance, endpoints for decolonization, and more…

Dear All, Greetings in the new year! I just tonight picked up on this fascinating BAA (Broad Agency Announcement) from CDC: BAA 75D301-23-R-72545 as described on this general overview webpage: https://sam.gov/opp/15229982f7c348f69fd35e9a0add8aba/view The BAA itself  Timeline: Initial white papers (max 4 pages, see page 76 of the BAA for details) are due by 3 Feb 2023; Invitations for

Read More »

Application calls! ENABLE-2, BARDA BAA! Ho, ho, ho!

Dear All, Two funding opportunities to call to your attention! First, ENABLE-2 has just launched an Open Call for antibacterial programs throughout Europe. The ENABLE-2 platform supports the development of direct-acting systemic antibacterial compounds (potentiator molecules are also in scope, e.g. β-lactamase inhibitors) by providing experimental support and expert advice. The goal of ENABLE-2 is

Read More »

RFP: Support for creating Antimicrobial Stewardship Centers of Excellence

Dear All, I wrote in a 26 Oct 2021 newsletter about an RFP focused on Antimicrobial Stewardship (AMS) activities to address health inequities arising from socioeconomic disparities. The core concept is that AMR disproportionally impacts underserved patient communities world-wide. Racial minorities, ethnic minorities, and elderly patients in both developed and developing economies are all at risk. Building on

Read More »

RFP: Climate-Sensitive Infectious Disease Modelling

Dear All, And now for something really different! With the recent GRAM report (20 Jan 2022 newsletter) showing that AMR is linked to more deaths that HIV or malaria (#AMRSOS! Andrew Jack and FT team have some great graphics for this … check them out!), we now have an absolutely fascinating call from Wellcome Trust for

Read More »

PAR Foundation grants: Early career support, prevention of AMR in the elderly

Dear All, The Stockholm-based PAR Foundation (aka, the Foundation to Prevent Antibiotic Resistance) has announced two groups of grant opportunities. First, early career grants of up to ~€30k are available to support 1-year projects on prevention of antibiotic resistance. What: “The aim of this call is to improve the ability and interest of promising early-career individuals

Read More »

BARDA and NIAID RFPs addressing bacterial, fungal, and viral threats

Dear All, When it rains, it pours … and sometimes in a good way! Today saw the release of requests for proposals by NIAID and BARDA for therapeutics (antibacterial, antifungal, antiviral), vaccines (again, all 3 areas), and diagnostics. It’s an impressive list of opportunities that covers both biothreat pathogens as well as NIAID’s list of

Read More »
Scroll to Top